Literature DB >> 28439640

The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes.

Stef J Bloem1, Bart O Roep2,3.   

Abstract

The role of B lymphocytes in the pathogenesis of type 1 diabetes in humans is not entirely evident. These cells are presumed to be important, but this assumption is largely based on animal models of autoimmune diabetes, where compelling evidence for the contribution of both B lymphocytes and insulin-specific autoantibodies to this disease is in place. For humans, this is much less the case; the exact way in which B lymphocytes and/or autoantibodies may contribute to type 1 diabetes is not yet known but the possibilities include a pathogenic function ('fire'), or they may represent a surrogate of loss of immune tolerance to beta cells ('smoke') or, indeed, they could be a marker of an attempt at immune regulation ('ice water'). In this issue of Diabetologia, a study by Willcox et al (DOI: 10.1007/s00125-017-4221-7 ) adds new information but no greater clarity on the relevance of B lymphocytes in type 1 diabetes, showing a decrease in germinal centre frequencies in donors with recent-onset type 1 diabetes compared with control donors and donors with longstanding type 1 diabetes. These new findings may guide the research community to design experiments to unambiguously define whether B lymphocytes or their products function as fire, smoke or perhaps ice water in the immunopathogenesis of type 1 diabetes.

Entities:  

Keywords:  B lymphocytes; Germinal centre; Immunopathogenesis; Islet autoantibodies; Lymphoid follicles; Pancreas-draining lymph nodes

Mesh:

Substances:

Year:  2017        PMID: 28439640     DOI: 10.1007/s00125-017-4284-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  37 in total

Review 1.  Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal.

Authors:  B O Roep; M Atkinson
Journal:  Diabetologia       Date:  2004-10-13       Impact factor: 10.122

Review 2.  Can we really predict IDDM?

Authors:  P J Bingley; E Bonifacio; E A Gale
Journal:  Diabetes       Date:  1993-02       Impact factor: 9.461

3.  Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine.

Authors:  Tihamer Orban; Janos Tibor Kis
Journal:  Ther Adv Endocrinol Metab       Date:  2011-02       Impact factor: 3.565

4.  Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.

Authors:  Siri Atma W Greeley; Makoto Katsumata; Liping Yu; George S Eisenbarth; Daniel J Moore; Heidi Goodarzi; Clyde F Barker; Ali Naji; Hooman Noorchashm
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

5.  Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.

Authors:  Kevan C Herold; Mark D Pescovitz; Paula McGee; Heidi Krause-Steinrauf; Lisa M Spain; Kasia Bourcier; Adam Asare; Zhugong Liu; John M Lachin; H Michael Dosch
Journal:  J Immunol       Date:  2011-07-20       Impact factor: 5.422

6.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

7.  The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes.

Authors:  Shilpa Oak; Lisa K Gilliam; Mona Landin-Olsson; Carina Törn; Ingrid Kockum; Christina R Pennington; Merrill J Rowley; Michael R Christie; J Paul Banga; Christiane S Hampe
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-26       Impact factor: 11.205

8.  Dendritic Cells Guide Islet Autoimmunity through a Restricted and Uniquely Processed Peptidome Presented by High-Risk HLA-DR.

Authors:  Menno van Lummel; Peter A van Veelen; Arnoud H de Ru; George M C Janssen; Jos Pool; Sandra Laban; Antoinette M Joosten; Tatjana Nikolic; Jan W Drijfhout; M Luisa Mearin; Henk J Aanstoot; Mark Peakman; Bart O Roep
Journal:  J Immunol       Date:  2016-03-04       Impact factor: 5.422

9.  B-lymphocyte depletion with rituximab and β-cell function: two-year results.

Authors:  Mark D Pescovitz; Carla J Greenbaum; Brian Bundy; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Antoinette Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane K Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Diabetes Care       Date:  2013-09-11       Impact factor: 19.112

10.  Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo.

Authors:  Arnaud Zaldumbide; Gonnie Alkemade; Françoise Carlotti; Tatjana Nikolic; Joana Rf Abreu; Marten A Engelse; Anja Skowera; Eelco J de Koning; Mark Peakman; Bart O Roep; Rob C Hoeben; Emmanuel Jhj Wiertz
Journal:  Mol Ther       Date:  2013-05-21       Impact factor: 11.454

View more
  11 in total

Review 1.  Immunological Monitoring in Beta Cell Replacement: Towards a Pathophysiology-Guided Implementation of Biomarkers.

Authors:  Fanny Buron; Sophie Reffet; Lionel Badet; Emmanuel Morelon; Olivier Thaunat
Journal:  Curr Diab Rep       Date:  2021-04-25       Impact factor: 4.810

Review 2.  Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes.

Authors:  Chelsea Gootjes; Jaap Jan Zwaginga; Bart O Roep; Tatjana Nikolic
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 3.  Islet-Resident Dendritic Cells and Macrophages in Type 1 Diabetes: In Search of Bigfoot's Print.

Authors:  Henner Zirpel; Bart O Roep
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-12       Impact factor: 5.555

Review 4.  Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials.

Authors:  Jessica S Suwandi; Tatjana Nikolic; Bart O Roep
Journal:  Front Immunol       Date:  2017-11-22       Impact factor: 7.561

Review 5.  Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).

Authors:  Bart O Roep; Sofia Thomaidou; René van Tienhoven; Arnaud Zaldumbide
Journal:  Nat Rev Endocrinol       Date:  2020-12-08       Impact factor: 43.330

6.  Footprints of Immune Cells in the Pancreas in Type 1 Diabetes; to "B" or Not to "B": Is That Still the Question?

Authors:  Pia Leete; Noel G Morgan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

7.  Identifying Changes in Peripheral Lymphocyte Subpopulations in Adult Onset Type 1 Diabetes.

Authors:  Aina Teniente-Serra; Eduarda Pizarro; Bibiana Quirant-Sánchez; Marco A Fernández; Marta Vives-Pi; Eva M Martinez-Caceres
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561

8.  Interleukin-35 Prevents Development of Autoimmune Diabetes Possibly by Maintaining the Phenotype of Regulatory B Cells.

Authors:  Zhengkang Luo; Sara Lundin; Mariela Mejia-Cordova; Imane Hassani; Martin Blixt; Daisy Hjelmqvist; Joey Lau; Daniel Espes; Per-Ola Carlsson; Stellan Sandler; Kailash Singh
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 9.  From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes.

Authors:  Nicoline H M den Hollander; Bart O Roep
Journal:  Front Med (Lausanne)       Date:  2022-07-12

Review 10.  From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations.

Authors:  Ayman F Refaie; Batoul L Elbassiouny; Malgorzata Kloc; Omaima M Sabek; Sherry M Khater; Amani M Ismail; Rania H Mohamed; Mohamed A Ghoneim
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.